Up to 4,494,279 Shares of Common Stock

This prospectus relates to the resale from time to time of up to 4,494,279 shares of common stock, par value $0.0001 per share (the "Shares"), of Evommune, Inc. by the selling stockholders listed on page 37 (the "Selling Stockholders"), including their pledgees, assignees, donees, transferees or their respective successors-in-interest.

We will not receive any proceeds from the sale of the Shares offered by this prospectus.

Sales of the Shares by the Selling Stockholders may occur at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. The Selling Stockholders may sell the Shares to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the Selling Stockholders, the purchasers of the Shares, or both.

We are paying the cost of registering the Shares as well as various related expenses. The Selling Stockholders are responsible for all selling commissions, transfer taxes and other costs related to the offer and sale of their Shares. See "Plan of Distribution" for more information about how the Selling Stockholders may sell or dispose of their Shares.

Our common stock is traded on the New York Stock Exchange ("NYSE") under the symbol "EVMN." On April 16, 2026, the last reported sale price of our common stock was $26.77 per share.

We are an "emerging growth company" and a "smaller reporting company" as defined under the federal securities laws and, as such, will be subject to certain reduced public company reporting requirements for this prospectus. See "Prospectus Summary—Implications of Being an Emerging Growth Company and a Smaller Reporting Company."